الفهرس 
Preparation of recombinant HER2 (epidermal growth factor) antigen
AbstractOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Breast cancer is a major worldwide problem that affects humans and animals as well. Breast cancer is considered a major malignancy and one of the most common cancers together with lung and colon cancer. Therapeutic backbones for breast cancer include surgery, chemotherapy, radiation, targeted therapy and immunotherapy. However, these approaches have their limitations and continuous research is undergoing to produce a more effective treatment for metastatic breast cancer. A promising recent approach is directed to the production of specific nanobodies against HER2 instead of monoclonal antibodies. HER2 is an important prognostic marker and therapeutic target for breast cancer and other tumors. A synthesized HER2 gene (3738 bp) cloned into PUC57 plasmid was obtained from Biomatikincorporation (USA). This fragment was isolated as a PCR amplicon using specific primers and high fidelity polymerase enzyme. Recombinant HER2 protein was prepared by cloning this synthesized HER2 gene into a pET expression vector and its production in E. coli BL21 bacterial host cells. The produced recombinant protein was confirmed by SDS-PAGE and western blot using nickel histidine detector conjugate. from the current study, we concluded that recombinant HER2 protein production can be produced efficiently and will be used for further diagnostic and therapeutic purposes